Welcome to our dedicated page for Amarin news (Ticker: AMRN), a resource for investors and traders seeking the latest updates and insights on Amarin stock.
Amarin Corporation plc (NASDAQ: AMRN) is a global pharmaceutical company focused on cardiovascular disease and the development and commercialization of icosapent ethyl, marketed as VASCEPA in the United States and other regions and as VAZKEPA in Europe. The AMRN news feed on Stock Titan brings together Amarin’s press releases and related coverage so investors can follow how the company is executing on its cardiovascular strategy.
News about Amarin frequently covers clinical and scientific developments around its REDUCE-IT cardiovascular outcomes trial and subsequent post hoc analyses, including presentations at major conferences such as the American Heart Association Scientific Sessions, the European Society of Cardiology Congress and the Canadian Cardiovascular Congress. These updates often explore cardiovascular risk reduction in high-risk subgroups, mechanistic insights into eicosapentaenoic acid, and evolving guideline and regulatory perspectives on triglyceride-lowering therapies.
Investors can also expect regular updates on Amarin’s commercial performance and operating model. Recent releases have discussed the transition to a fully partnered international commercialization strategy, an exclusive long-term license and supply agreement with Recordati to commercialize VAZKEPA across 59 European-focused countries, restructuring efforts to reduce operating expenses, and commentary on market dynamics for therapies targeting elevated triglycerides and severe hypertriglyceridemia.
Regulatory and policy developments are another recurring theme, including Amarin’s statements on FDA labeling changes for fenofibrate products and the implications for cardiovascular risk management. Together, these categories of news provide a view into how Amarin positions VASCEPA/VAZKEPA within global cardiovascular care, how its partnerships evolve, and how scientific data may influence future prescribing patterns. Bookmark this page to monitor AMRN news on clinical data, partnerships, financial updates and regulatory developments in one place.
Summary not available.
Summary not available.
Amarin Corporation plc (NASDAQ: AMRN) will host a conference call on May 3, 2023, at 8:00 a.m. ET to discuss its first quarter 2023 financial results. This event will take place following the release of the financial results in pre-market hours. Investors can access the call through the company’s website or by dialing in. The company, known for its innovative approach to cardiovascular disease management, has rapidly evolved from a research foundation to commercial expansion, emphasizing the treatment of cardiovascular risks not addressed by traditional therapies.
Amarin Corporation plc (NASDAQ:AMRN) has appointed Aaron Berg as Interim President and CEO and Oliver O’Connor as a new independent Director, effective immediately. Berg, who has over 25 years of biopharmaceutical experience and has been with Amarin since 2012, aims to advance the company's strategy in cardiovascular disease management and optimize operations. His leadership is expected to enhance the value of VASCEPA for patients globally. O’Connor brings extensive experience in government, policy, and biopharma, which the board believes will be crucial for unlocking VASCEPA’s value outside the U.S. The board is working to identify a permanent CEO.
Amarin Corporation (NASDAQ:AMRN) has received regulatory approval from Israel's Ministry of Health for VAZKEPA (icosapent ethyl). This approval allows the use of VAZKEPA to reduce the risk of cardiovascular events in adult statin-treated patients with elevated triglycerides and other high-risk characteristics. Heart disease is a significant health concern in Israel, being the second leading cause of death among individuals aged 45 and older. Amarin is actively pursuing partnerships and will begin preparing for pricing and reimbursement strategies in Israel starting in 2024.
Amarin Corporation (NASDAQ: AMRN) has announced that its new board, appointed two weeks ago, is committed to enhancing shareholder value. They emphasize VASCEPA's potential to improve cardiovascular outcomes and generate cost savings for payors. The board recognizes the challenges ahead but aims to cultivate a successful company culture for employees. They believe VASCEPA can unlock significant shareholder value as they engage actively with shareholders. The company, headquartered in Dublin and Bridgewater, New Jersey, is dedicated to advancing cardiovascular disease management.
Amarin Corporation plc (NASDAQ: AMRN) announced the immediate resignation of all seven independent non-Sarissa board members to facilitate Sarissa's control of the company. This decision follows shareholder backing for Sarissa's proposed directors during the 2023 Special Meeting of Shareholders. The resigning board members expressed confidence in Amarin's potential and wished the incoming Sarissa directors success in enhancing shareholder value. Amarin is focused on evolving its cardiovascular disease management strategies through scientific research and clinical trials, with a commitment to understanding cardiovascular risk beyond traditional therapies.
Amarin Corporation plc (NASDAQ:AMRN) presented new in vitro data at the ACC.23/WCC conference, highlighting the antithrombotic and antioxidant effects of eicosapentaenoic acid (EPA). The findings support EPA's role in reducing cardiovascular events, particularly in patients with elevated triglycerides. Notably, EPA inhibited lipoprotein oxidation by 89%, outperforming docosahexaenoic acid (DHA). The REDUCE-IT trial further substantiates these results, demonstrating significant reductions in ischemic events without increased bleeding risks. This data enhances confidence in the therapeutic potential of EPA and emphasizes its unique benefits compared to other oils.
Amarin Corporation has announced a new post-hoc analysis from the REDUCE-IT study, demonstrating that icosapent ethyl (IPE) significantly reduces the risk of first and total ischemic events by 37% and 36% respectively for patients with recent acute coronary syndrome (ACS), without increasing bleeding risks. The analysis included 840 patients with recent ACS and 3,651 patients with ACS over 12 months. Notably, the absolute risk reduction was 9.3% for first events with an NNT of 11. These findings were presented at the American College of Cardiology's annual session in New Orleans.
Amarin Corporation (NASDAQ:AMRN) announced its fourth quarter and full year 2022 results, reporting a net income of $0.9 million in Q4 2022, down from $14.7 million in Q4 2021. Total revenues for Q4 2022 were $90.2 million, a 38% decline compared to the previous year, driven by decreased sales volume of VASCEPA due to generic competition. The company generated positive free cash flow of $4 million in Q4 2022 and expects to exceed its cost savings target of $100 million in 2023. Positive progress was made in Europe with pricing secured in five markets and further negotiations ongoing, projecting a potential $1 billion peak revenue opportunity in the region.